	US 12,109,248 B2
	Method for isolating and detecting cancer stem cells
Vincent Carre, Jabreille les Bordes (FR); and Aurélie Lacroix, Panazol (FR)
Assigned to Sylvain Gnaho, Bonneval (FR)
Appl. No. 16/979,062
Filed by CARCIDIAG BIOTECHNOLOGIES, Gueret (FR)
PCT Filed Mar. 7, 2019, PCT No. PCT/FR2019/050516 § 371(c)(1), (2) Date Sep. 8, 2020, PCT Pub. No. WO2019/171010, PCT Pub. Date Sep. 12, 2019.
Claims priority of application No. 18/00202 (FR), filed on Mar. 8, 2018.
Prior Publication US 2021/0052697 A1, Feb. 25, 2021
Int. Cl. A61K 38/16 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01); C07K 14/42 (2006.01); C12N 5/095 (2010.01); G01N 33/574 (2006.01)

CPC A61K 38/168 (2013.01) [A61K 47/557 (2017.08); A61K 47/6923 (2017.08); C07K 14/42 (2013.01); C12N 5/0695 (2013.01); G01N 33/57484 (2013.01)]

6 Claims

1. An in vitro method of detecting cancer stem cells of hormone-dependent cancer target organs, the method comprising contacting a biological sample with at least two labeled lectins, wherein the lectins are Maackia amurensis lectin II (MAH-II), and Euonymus europaeus lectin (EEL), and thereby labeling and detecting cancer stem cells from an organ of hormone-dependent cancer, wherein the at least two lectins are in equal amount or in a 2:1 ratio by weight, and wherein the organ is breast, uterus, or ovaries.